Updated: Jun 3, 2021, 08:40 AM IST
The paediatric trials for the COVID-19 vaccine manufactured by the Bharat Biotech, Covaxin has started at Patna`s All India Institute of Medical Sciences (AIIMS). Covaxin received the Drugs Controller General of India (DCGI) nod to conduct clinical trials in children on May 11.
Dr VK Paul, Member (Health), Niti Aayog had earlier said, Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.
The Covaxin trials are also slated to take place in 525 subjects at various sites, including AIIMS, Delhi, and Meditrina Institute of Medical Sciences, Nagpur.
Loading the player.
India watching Singapore COVID-19 situation; precautions in place against new strain: Hardeep Puri
Aviation Minister Hardeep Singh Puri Tuesday said the Centre is taking all precautions and keeping an eye on the situation in Singapore after Delhi Chief Minister Arvind Kejriwal appealed to it to cancel all flights with the city-state as a very dangerous coronavirus strain has been detected there.
US COVID-19 vaccines effective against B.1.617 variant found in India
COVID-19 vaccines that are available in the United States are effective against the deadly variant that was first detected in India, top US health officials said on Tuesday. The B.1.617 virus variant, first identified in India last year, has been classified as a variant of concern at the global level by the World Health Organisation.